Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.03 EPS
Analysts forecast that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report earnings of ($0.03) per share for the current quarter, according to Zacks. Eight analysts have issued estimates for Neurocrine Biosciences’ earnings, with estimates ranging from ($0.79) to $0.39. Neurocrine Biosciences reported earnings of ($0.51) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 94.1%. The company is expected to announce its next earnings results on Tuesday, February 13th.
According to Zacks, analysts expect that Neurocrine Biosciences will report full year earnings of ($1.74) per share for the current financial year, with EPS estimates ranging from ($2.52) to ($1.31). For the next fiscal year, analysts expect that the business will post earnings of ($0.37) per share, with EPS estimates ranging from ($1.58) to $2.00. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter last year, the business earned ($0.43) EPS.
Several research analysts recently commented on NBIX shares. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a report on Thursday, September 7th. Jefferies Group LLC reiterated a “buy” rating and issued a $69.00 target price (up previously from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BMO Capital Markets reiterated an “outperform” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 5th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a report on Thursday, September 21st. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $78.88.
In other news, insider Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the sale, the insider now directly owns 101,790 shares in the company, valued at approximately $5,852,925. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kyle Gano sold 24,818 shares of Neurocrine Biosciences stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the sale, the insider now owns 84,596 shares in the company, valued at $6,010,545.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 110,810 shares of company stock worth $6,797,998. 4.80% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its position in shares of Neurocrine Biosciences by 14.5% during the 3rd quarter. Wells Fargo & Company MN now owns 945,368 shares of the company’s stock valued at $57,931,000 after acquiring an additional 119,383 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of Neurocrine Biosciences by 81.0% during the 3rd quarter. Schroder Investment Management Group now owns 37,105 shares of the company’s stock valued at $2,204,000 after acquiring an additional 16,609 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at about $246,000. Legal & General Group Plc boosted its position in shares of Neurocrine Biosciences by 14.6% during the 3rd quarter. Legal & General Group Plc now owns 36,497 shares of the company’s stock valued at $2,237,000 after acquiring an additional 4,638 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at about $1,457,000.
Shares of Neurocrine Biosciences (NASDAQ NBIX) traded up $0.04 on Friday, reaching $75.46. 768,500 shares of the company traded hands, compared to its average volume of 1,130,864. Neurocrine Biosciences has a 12-month low of $37.35 and a 12-month high of $75.98. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.